Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza And Osiris Ink Stem Cell Partnership

July 7, 2008 | A version of this story appeared in Volume 86, Issue 27

Lonza has formed a clinical development and commercial manufacturing agreement with Osiris Therapeutics for the biotech firm's adult stem cell therapy, Prochymal. As part of the agreement, Lonza will build a current Good Manufacturing Practice-certified allogenic manufacturing facility at its site in Walkersville, Md., with capacity to produce cell culture media for therapeutic applications. Prochymal is in Phase III trials for indications including Crohn's disease. Lonza describes the new plant as a multi-million-dollar project and says it's the first commercial-scale plant of its kind.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.